CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Ruxolitinib 1.5% Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05787860
NCT05787860Phase 2Completed
CompareCT.gov

Characterizing the Molecular Cutaneous Phenotype of Seborrheic Dermatitis and Treatment Response to Ruxolitinib 1.5% Cream

Icahn School of Medicine at Mount Sinai·interventional·Posted Mar 28, 2023·Updated May 6, 2025

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib 1.5% Cream for Seborrheic Dermatitis. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Dermatitis
CountriesUnited States
CollaboratorsIncyte Corporation

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 28, 2023
Enrollment StartNov 15, 2022
Primary CompletionJan 26, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.3 years ago

Interventions

Ruxolitinib 1.5% Creamdrug

topical ruxolitinib 1.5% cream twice daily for 4 weeks